MC1R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Nuclear warfare, also known as atomic warfare, is a military conflict or prepared political strategy that deploys nuclear weaponry. Nuclear weapons are weapons of mass destruction; in contrast to conventional warfare, nuclear warfare can produce significantly more destruction in a much shorter time and can have a long-lasting radiological result. A large nuclear exchange would kill hundreds of millions of people. It would have long-term effects, from the fallout released, and could also lead to secondary effects, such as nuclear winter, nuclear famine, and societal collapse. A global nuclear war with current national stockpiles may lead to various devastating scenarios, including human extinction. As of 2026, the first and only use of nuclear weapons in armed conflict was the United States atomic bombings of Hiroshima and Nagasaki, on August 6 and 9, 1945, in the final days of World War II. The two bombings resulted in the deaths of between 150,000 and 246,000 people. A debate continues over ethical, legal, and military aspects of the bombings, including their role in the surrender of Japan. The Cold War prompted the nuclear arms race. Nuclear weapons were later developed by the Soviet Union (1949), the United Kingdom (1952), France (1960), and China (1964). In 1974, India, and in 1998, Pakistan, with a history of conflict, developed nuclear weapons. Israel (1960s) and North Korea (2006) also developed nuclear weapons.
In the initial stages of allergy, a type I hypersensitivity reaction against an allergen encountered for the first time and presented by a professional antigen-presenting cell causes a response in a type of immune cell called a TH2 lymphocyte, a subset of T cells that produce a cytokine called interleukin-4 (IL-4). These TH2 cells interact with other lymphocytes called B cells, whose role is the production of antibodies. Coupled with signals provided by IL-4, this interaction stimulates the B cell to begin production of a large amount of a particular type of antibody known as IgE. Secreted IgE circulates in the blood and binds to an IgE-specific receptor (a kind of Fc receptor called FcεRI) on the surface of other kinds of immune cells called mast cells and basophils, which are both involved in the acute inflammatory response. At this stage, the IgE-coated cells are sensitized to the allergen. If later exposure to the same allergen occurs, the allergen can bind to IgE molecules held on the surface of the mast cells or basophils. Cross-linking of the IgE and Fc receptors occurs when more than one IgE-receptor complex interacts with the same allergenic molecule and activates the sensitized cell. Activated mast cells and basophils undergo a process called degranulation, during which they release histamine and other inflammatory chemical mediators (cytokines, interleukins, leukotrienes, and prostaglandins) from their granules into the surrounding tissue causing several systemic effects, such as vasodilation, mucous secretion, nerve stimulation, and smooth muscle contraction.
In metabolism research, tritium and 14C-labeled glucose are commonly used in glucose clamps to measure rates of glucose uptake, fatty acid synthesis, and other metabolic processes. While radioactive tracers are sometimes still used in human studies, stable isotope tracers such as 13C are more commonly used in current human clamp studies. Radioactive tracers are also used to study lipoprotein metabolism in humans and experimental animals. In medicine, tracers are applied in a number of tests, such as 99mTc in autoradiography and nuclear medicine, including single-photon emission computed tomography (SPECT), positron emission tomography (PET) and scintigraphy. The urea breath test for helicobacter pylori commonly used a dose of 14C labeled urea to detect h. pylori infection. If the labeled urea was metabolized by h. pylori in the stomach, the patient's breath would contain labeled carbon dioxide. In recent years, the use of substances enriched in the non-radioactive isotope 13C has become the preferred method, avoiding patient exposure to radioactivity. In hydraulic fracturing, radioactive tracer isotopes are injected with hydraulic fracturing fluid to determine the injection profile and location of created fractures. Tracers with different half-lives are used for each stage of hydraulic fracturing. In the United States amounts per injection of radionuclide are listed in the US Nuclear Regulatory Commission (NRC) guidelines. According to the NRC, some of the most commonly used tracers include antimony-124, bromine-82, iodine-125, iodine-131, iridium-192, and scandium-46.
Sources: en.wikipedia.org
== Chemical Modifications == The general purpose of HA modifications is to improve certain properties such as biocompatibility, permeation, and sustained drug release. It can also be modified to test the functionality of certain groups, such as the carboxyl or hydroxyl groups. These improvements to HA are achieved through cross-linking and bioconjugation with various molecules, such as acid derivatives, ketones, aldehydes, biopolymers, and probes. There are three sites on HA that can be modified: the Carboxylic acid group (COOH), the hydroxyl group (OH), and the N-acetyl group (NHCOH3). Modifications of the carboxylic acid group include amidation, Ugi condensation, and ester formation. Modifications of the hydroxyl group include ether formation, hemiacetal formation, ester formation, carbamate formation, and oxidation with sodium periodate. Modifications of the N-acetyl group include deacetylation, followed by amidation or Ugi condensation.
== Sources == U7-CNTX-Pn1a is naturally found in the venom of Phoneutria nigriventer, often referred to as the Brazilian wandering or 'armed' spider. Additionally, the recombinant protein has been produced based on the amino acid sequence derived from the isolated neurotoxin.
Jonathan Lavine (1988), business executive, co-managing partner of Bain Capital and chief investment officer of Bain Capital Credit Anita Lo (1988), celebrity chef and restaurateur Danielle Maged (1989), Fox Networks Group executive Joanne Ooi (1989), former creative director of Shanghai Tang; CEO of Clean Air Network and Plukka Paul Greenberg (1990), former CEO of CollegeHumor and current CEO of Nylon Prem Parameswaran (1990), CFO of Eros International Plc and member of the President's Advisory Commission on Asian Americans and Pacific Islanders William von Mueffling (1990), hedge fund manager, president of Cantillon Capital Management Christoph Westphal (1990), biomedical entrepreneur, founder of Alnylam Pharmaceuticals, Acceleron Pharma, and OvaScience Marko Ahtisaari (1991), Finnish entrepreneur; founding CEO of Dopplr; son of Martti Ahtisaari, tenth President of Finland and Nobel Peace Prize laureate Claude Arpels (1991), investor, entrepreneur, grandson of Julien Arpels and heir to the Van Cleef & Arpels fortune Tewodros Ashenafi (1991), founder and CEO of Ethiopian company SouthWest Energy Jack Hidary (1991), financier and entrepreneur, co-founder of the Automotive X Prize and EarthWeb/Dice Inc. E. Javier Loya (1991), CEO of OTC Global Holdings and minority owner in Houston Texans Zia Chishti (1992), entrepreneur and founder of Afiniti and Align Technology Erik Feig (1992), Lionsgate co-president and former president of Summit Entertainment; producer of Step Up series, Escape Plan, Mr. & Mrs.
Sources: en.wikipedia.org
=== Menu options === The menus below are adapted from lists available on the website of the Defense Logistics Agency (DLA). UGR menus are regularly modified to improve their variety, nutrition, and efficiency. As the DLA does not regularly publish UGR menus. The lists below use the 2020 menu for the UGR-H&S, 2023 menu for the UGR-A, 2014 menu for the UGR-M, and 2021 menu for the UGR-E. Note that the lists below do not include milk, bread, fruit, or salad supplements, or items standard to most UGRs such as regular coffee and hot sauce.
== History == The chain was founded in Eugene by Ron Fraedrick (1928–2015), who opened the first restaurant near his alma mater, the University of Oregon, at 13th Avenue and High Street in January 1960. In 1962, the first Taco Time franchise opened in White Center, Washington. In the 1970s, the company expanded to 48 restaurants in seven Western states. In 1978, the company franchised its first international restaurant in Lethbridge, Alberta, Canada. In 1979, Taco Time Northwest became a licensee with the rights to franchise and operate the Taco Time concept independently. Taco Time Northwest's operating region includes western Washington from Longview to the Canada–United States border and the eastern Washington cities of Wenatchee and Moses Lake. In 1984, food at a location in The Dalles was allegedly poisoned by members of the Rajneesh movement in a bioterror attack. Taco Time has since expanded, now holding more than 300 franchises in the United States and Canada. They previously had locations in Kuwait, Greece, and Netherlands Antilles (Curaçao) which seem to have closed. In 2003, the company was bought by Kahala Brands of Scottsdale, Arizona.
KDEL is a target peptide sequence motif in mammals and plants located on the C-terminal end of the amino acid structure of a protein. The KDEL sequence prevents a protein from being secreted from the endoplasmic reticulum (ER) and facilitates its return if it is accidentally exported. A protein with a functional KDEL motif will be retrieved from the Golgi apparatus by retrograde transport to the ER lumen. It also targets proteins from other locations (such as the cytoplasm) to the ER. Proteins can only leave the ER after this sequence has been cleaved off. The abbreviation KDEL is formed by the corresponding letters to each amino acid. This letter system was defined by the IUPAC and IUBMB in 1983, and is as follows:
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.